MilliporeSigma Makes Major Investment in New Singapore Laboratory
- First GMP BioReliance® biosafety testing lab in Asia Pacific offering critical testing services to bring life-changing therapies to market
- Extensive range of upstream and downstream bioprocessing solutions through M Lab™ Collaboration Center, Media Development Services Lab and imMEDIAte Advantage™ Lab
Burlington, Massachusetts, September 18, 2018 – MilliporeSigma today announced the opening of a new 3,800-square-meter laboratory in Singapore. The new, $20 million SGD lab is the first of its kind outside of the US and UK, and the first in Singapore. Biologics testing is a major step in the drug development process to ensure sterility, safety and overall quality of customers’ biological drug products.
"This investment underscores our commitment to Singapore as an important hub for our company,” said Udit Batra, CEO, MilliporeSigma. “Our new BioReliance® lab in Singapore is the first of its kind for biomanufacturing in this region. And our reimagined M Lab™ Collaboration Center, which recreates an actual manufacturing environment, emerged as part of our close work with the Singapore Economic Development Board. We thank the Board for their partnership as we continue to serve the growing needs of our pharma and biotech customers in bringing new therapies to market.”
Singapore is at the heart of the Asia Pacific region, and is the Asian headquarters to many multinational pharmaceutical organizations that have a significant manufacturing footprint on the island. Its vibrant ecosystem has also attracted local Life Science companies and start-ups to establish a presence here.
“The establishment of MilliporeSigma’s biosafety testing lab will strengthen Singapore’s competitiveness as a leading global site for biologics manufacturing,” said Dr. Beh Swan Gin, chairman of Singapore Economic Development Board. “The company’s M Lab™ Collaboration Centre is also a welcome addition to Singapore’s life science innovation ecosystem. Both projects will provide Singaporeans with the opportunity to acquire highly-skilled and specialised capabilities.”
MilliporeSigma provides the industry’s most comprehensive portfolio of high-quality products, services and testing for biopharmaceutical manufacturing.
BioReliance® Biosafety Testing Lab
MilliporeSigma’s BioReliance® biosafety testing services portfolio delivers biosafety testing services to the global pharmaceutical and biotech industry. These crucial safety-testing services ensure the safe release of leading medicines to patients around the world.
M Lab™ Collaboration Center
MilliporeSigma’s M Lab™ Collaboration Center offers non-GMP lab space for training, hands-on demonstrations and process optimization, supported by MilliporeSigma’s technical experts. Designed to recreate an actual manufacturing environment, the center in Singapore is the latest addition to MilliporeSigma’s network of nine M Lab™ Collaboration Centers worldwide.
The flexible lab allows customers to recreate their specific processes for troubleshooting critical process issues without impacting their own production line. The center includes an upgraded suite of digital interactive applications for knowledge sharing and technical exploration.
MilliporeSigma is the Life Science business of Merck KGaA, Darmstadt, Germany — the world’s oldest pharmaceuticals and chemicals company, celebrating its 350th anniversary this year. The company is continuing its legacy of defining the future and leading the evolution of drug development and manufacturing of life-enhancing drugs, increasing the quality, safety and access to patients and at a reduced cost.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has five businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Life Science and Performance Materials – and generated sales of €15.3 billion in 2017. Almost 53,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Based on high demand expected to continue throughout the year and a very strong first quarter of 2021 with net sales of EUR 4.63 bn resulting in EBITDA pre of EUR 1.51 bn and EPS pre of EUR 2.18, ...